NEW YORK, Sept 19 - Human Genome Sciences (Nasdaq: HGSI) stock jumped 9 13/16, or 6.8 percent, to 153 13/16 in mid-morning trading Tuesday following an announcement on  Monday after the close of trading that the company’s board had approved a two-for-one stock split.

Shareholders will receive an additional common share for each share held at close-of-business on Sept. 28. The additional shares will be delivered on or about Oct. 5.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.